Literature DB >> 2532875

Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci.

E A Gorzynski1, D Amsterdam, T R Beam, C Rotstein.   

Abstract

The in vitro activities of teicoplanin and vancomycin were compared with those of six other antimicrobial agents against 460 bacteremic isolates of gram-positive cocci. Teicoplanin was as active as vancomycin but less active than ciprofloxacin against staphylococci. Teicoplanin was the most potent of all agents tested against enterococci and had excellent activity against pneumococci.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2532875      PMCID： PMC172808          DOI： 10.1128/AAC.33.11.2019

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  14 in total

1.  Anti-staphylococcal activity of teicoplanin, vancomycin, and other antimicrobial agents: the significance of methicillin resistance.

Authors:  V E Del Bene; J F John; J A Twitty; J W Lewis
Journal:  J Infect Dis       Date:  1986-08       Impact factor: 5.226

2.  An aminoglycoside disk sensitivity test for use with enterococci.

Authors:  S L Rosenthal; L F Freundlich
Journal:  J Antimicrob Chemother       Date:  1982-11       Impact factor: 5.790

3.  Species-specific resistance to antimocrobial synergism in Streptococcus faecium and Streptococcus faecalis.

Authors:  R C Moellering; O M Korzeniowski; M A Sande; C B Wennersten
Journal:  J Infect Dis       Date:  1979-08       Impact factor: 5.226

4.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

5.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  In vitro activity of ciprofloxacin (Bay o 9867).

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

7.  Teichomycin: in-vitro and in-vivo evaluation in comparison with other antibiotics.

Authors:  R Pallanza; M Berti; B P Goldstein; E Mapelli; E Randisi; R Scotti; V Arioli
Journal:  J Antimicrob Chemother       Date:  1983-05       Impact factor: 5.790

8.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

9.  Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria.

Authors:  A L Barry; R N Jones; T L Gavan; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

10.  Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.

Authors:  P Calain; K H Krause; P Vaudaux; R Auckenthaler; D Lew; F Waldvogel; B Hirschel
Journal:  J Infect Dis       Date:  1987-02       Impact factor: 5.226
View more
  13 in total

1.  Comparison of shunt infection incidence in high-risk subgroups receiving antibiotic-impregnated versus standard shunts.

Authors:  Scott L Parker; Frank J Attenello; Daniel M Sciubba; Giannina L Garces-Ambrossi; Edward Ahn; Jon Weingart; Benjamin Carson; George I Jallo
Journal:  Childs Nerv Syst       Date:  2008-11-05       Impact factor: 1.475

2.  Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci.

Authors:  F W Goldstein; A Coutrot; A Sieffer; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Penetration of teicoplanin into heart valves and subcutaneous and muscle tissues of patients undergoing open-heart surgery.

Authors:  U K Frank; E Schmidt-Eisenlohr; D Mlangeni; M Schindler; A Hoh; F Beyersdorf; F D Daschner
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

4.  Teicoplanin in cardiac surgery: intraoperative pharmacokinetics and concentrations in cardiac and mediastinal tissues.

Authors:  C Martin; P Bourget; M Alaya; A Sertin; C Atlani; K Ennabli; R Said
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.

Authors:  R N Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

6.  Comparative activity of teicoplanin and vancomycin against 400 penicillin susceptible and resistant Streptococcus pneumoniae. The French Study Group.

Authors:  F W Goldstein; P Geslin; J F Acar
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-01       Impact factor: 3.267

Review 7.  Teicoplanin: 10 years of clinical experience.

Authors:  M Trautmann; H Wiedeck; M Ruhnke; M Oethinger; R Marre
Journal:  Infection       Date:  1994 Nov-Dec       Impact factor: 3.553

Review 8.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci.

Authors:  D Shonekan; D Mildvan; S Handwerger
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

10.  Teicoplanin versus vancomycin for prophylaxis of experimental Enterococcus faecalis endocarditis in rats.

Authors:  J M Entenza; T Calandra; Y Moosmann; R Malinverni; M P Glauser
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.